MediumEndocrinologyType 2 diabetes with high cardiovascular riskau-amcau-racgpau-racp
A 58-year-old man with type 2 diabetes, obesity and hypertension has an HbA1c of 70 mmol/mol (8.6%) despite maximally tolerated metformin. eGFR is 70 mL/min/1.73 m². He has albuminuria and a 5-year absolute CVD risk of 18%. Which additional glucose-lowering agent is preferred to improve both glycaemic control and cardiovascular-renal outcomes?